Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

Mesenchymal stem cell secretions improve donor heart function following ex vivo cold storage

Wang M., Yan L., Li Q., Yang Y., Turrentine M., March K.

Animal Study on Cardiovascular Disease, published in J Thorac Cardiovasc Surg (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Thorac Cardiovasc Surg (2022)
Reported sample size
—
Source database
Europe PMC
PMID
32981709
PMCID
PMC7921217
DOI
10.1016/j.jtcvs.2020.08.095
Citations
18

Abstract (original English)

Objectives Heart transplantation is the gold standard of treatments for end-stage heart failure, but its use is limited by extreme shortage of donor organs. The time "window" between procurement and transplantation sets the stage for myocardial ischemia/reperfusion injury, which constrains the maximal storage time and lowers use of donor organs. Given mesenchymal stem cell (MSC)-derived paracrine protection, we aimed to evaluate the efficacy of MSC-conditioned medium (CM) and extracellular vesicles (EVs) when added to ex vivo preservation solution on ameliorating ischemia/reperfusion-induced myocardial damage in donor hearts. Methods Mouse donor hearts were stored at 0°C-4°C of Results Six-hour cold ischemia significantly impaired myocardial function, increased cell death, and reduced miR-199a-3p in implanted hearts versus Conclusions MSC-CM and MSC-EVs confer improved myocardial preservation in donor hearts during prolonged cold static storage and MSC-EVs can be used for intercellular transport of miRNAs in heart transplantation.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsMice, Inbred C57BLMiceMyocardial Reperfusion InjuryMicroRNAsOrgan Preservation SolutionsCulture Media, ConditionedCryopreservationHeart Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research